Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Wu, Jia Ru ^a   Hu, Chi Tan ^a   You, Ren In ^a   Ma, Pei Ling ^a   Pan, Siou Mei ^a   Lee, Ming Che ^a   Wu, Wen Sheng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; LZ 8; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; FUNGAL PROTEIN; LZ-8 PROTEIN, GANODERMA LUCIDUM;

ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MIGRATION INHIBITION; MOLECULAR PATHOLOGY; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANIMAL; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; MALE; METABOLISM; MOUSE; PATHOLOGY; SCID MOUSE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; FUNGAL PROTEINS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946096420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114495     Document Type: Article

References (59)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
2. Gao J, Inagaki Y, Song P, Qu X, Kokudo N, et al. (2012) Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res 65:23-30. doi: 10.1016/j.phrs.2011.11.011 PMID: 22138044
3. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687. doi: 10.1038/nrc1934 PMID: 16929323
4. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111-1118. doi: 10.1016/S1470-2045 (09) 70241-4 PMID: 19880065
5. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236. doi: 10.1002/hep. 20933 PMID: 16250051
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390. doi: 10.1056/NEJMoa0708857 PMID: 18650514
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 10:25-34. doi: 10.1016/S1470-2045 (08) 70285-7 PMID: 19095497
8. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, et al. (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908-943. doi: 10.1016/j.jhep. 2011.12.001 PMID: 22424438
9. Zhu AX (2012) Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 39:493-502. doi: 10.1053/j.seminoncol.2012.05.014 PMID: 22846866
10. Zhai B, Sun XY (2013) Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 5:345-352. doi: 10.4254/wjh.v5.i7.345 PMID: 23898367
11. Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5-S16. doi: 10.1053/j.gastro.2004.07.015 PMID: 15508102
12. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, et al. (2004) A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187-196. doi: 10.1007/s00432-003-0511-1 PMID: 14685850
13. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679-695. doi: 10. 1016/j.cell.2006.11.001 PMID: 17110329
14. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375-379. doi: 10.1038/35077241 PMID: 11357145
15. Christofori G (2006) New signals from the invasive front. Nature 441:444-450. doi: 10.1038/nature04872 PMID: 16724056
16. Gao CF, Vande Woude GF (2005) HGF/SF-Met signaling in tumor progression. Cell Res 15:49-51. doi: 10.1038/sj.cr.7290264 PMID: 15686627
17. Buijs JT, Stayrook KR, Guise TA (2011) TGF-beta in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron 4:261-281. doi: 10.1007/s12307-011-0075-6 PMID: 21748439
18. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89-103. doi: 10.1038/nrc3205 PMID: 22270953
19. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25:862-866. doi: 10. 1002/hep. 510250413 PMID: 9096589
20. Osada S, Kanematsu M, Imai H, Goshima S (2008) Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 55:544-549. PMID: 18613405
21. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, et al. (2009) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491-503. doi: 10.1002/hep. 22639 PMID: 19065669
22. Wang ZL, Liang P, Dong BW, Yu XL, Yu de J (2008) Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg 12:327-337. doi: 10.1007/s11605-007-0310-0 PMID: 17943391
23. Kaposi-Novak P (2009) Comparative genomic classification of human hepatocellular carcinoma. Magy Onkol 53:61-67. doi: 10.1556/MOnkol.53.2009.1.9 PMID: 19318328
24. Ogunwobi OO, Liu C (2011) Hepatocyte growth factor upregulation promotes carcinogenesis and epithelialmesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 28:721-731. doi: 10.1007/s10585-011-9404-x PMID: 21744257
25. Jiang Y, Xu W, Lu J, He F, Yang X (2001) Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun 286:1123-1130. doi: 10.1006/bbrc.2001.5521 PMID: 11527416
26. Ogunwobi OO, Wang T, Zhang L, Liu C (2012) Cyclooxygenase-2 and Akt mediate multiple growth-factorinduced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol 27:566-578. doi: 10.1111/j.1440-1746.2011.06980.x PMID: 22097969
27. Goyal L, Muzumdar MD, Zhu AX (2013) Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 19:2310-2318. doi: 10.1158/1078-0432. CCR-12-2791 PMID: 23388504
28. You H, Ding W, Dang H, Jiang Y, Rountree CB (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54:879-889. doi: 10.1002/hep. 24450 PMID: 21618573
29. Chan SL, Yeo W (2012) Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 27:862-872. doi: 10.1111/j.1440-1746.2012.07096.x PMID: 22369685
30. Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, et al. (1995) The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10:1631-1638. PMID: 7731718
31. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, et al. (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261-271. doi: 10.1016/0092-8674 (94) 90318-2 PMID: 7513258
32. Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834-848. doi: 10.1038/nrm3012 PMID: 21102609
33. Zhu K, Kong X, Zhao D, Liang Z, Luo C (2014) c-MET kinase inhibitors: a patent review (2011-2013). Expert Opin Ther Pat 24:217-230. doi: 10.1517/13543776.2014.864279 PMID: 24266843
34. Diaz D, Ford KA, Hartley DP, Harstad EB, Cain GR, et al. (2013) Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicol Appl Pharmacol 266:86-94. doi: 10.1016/j.taap. 2012.10.026 PMID: 23142475
35. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, et al. (2013) A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 108:21-24. doi: 10.1038/bjc.2012.556 PMID: 23287988
36. Xue Q, Ding Y, Shang C, Jiang C, Zhao M (2008) Functional expression of LZ-8, a fungal immunomodulatory protein from Ganoderma lucidium in Pichia pastoris. J Gen Appl Microbiol 54:393-398. doi: 10. 2323/jgam.54.393 PMID: 19164882
37. Lin YL, Liang YC, Tseng YS, Huang HY, Chou SY, et al. (2009) An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. J Leukoc Biol 86:877-889. doi: 10.1189/jlb.0708441 PMID: 19498044
38. Lin CC, Yu YL, Shih CC, Liu KJ, Ou KL, et al. (2011) A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunol Immunother 60:1019-1027. doi: 10.1007/s00262-011-1016-4 PMID: 21499904
39. Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF (2011) Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer 63:1085-1094. doi: 10.1080/01635581.2011.601845 PMID: 21888505
40. Liao CH, Hsiao YM, Hsu CP, Lin MY, Wang JC, et al. (2006) Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from Ganoderma tsugae in A549 human lung adenocarcinoma cell line. Mol Carcinog 45:220-229. doi: 10.1002/mc.20161 PMID: 16402390
41. Wu CT, Lin TY, Hsu HY, Sheu F, Ho CM, et al. (2011) Ling Zhi-8 mediates p53-dependent growth arrest of lung cancer cells proliferation via the ribosomal protein S7-MDM2-p53 pathway. Carcinogenesis 32:1890-1896. doi: 10.1093/carcin/bgr221 PMID: 21983128
42. Wang PH, Yang SF, Chen GD, Han CP, Chen SC, et al. (2007) Human nonmetastatic clone 23 type 1 gene suppresses migration of cervical cancer cells and enhances the migration inhibition of fungal immunomodulatory protein from Ganoderma tsugae. Reprod Sci 14:475-485. doi: 10.1177/1933719107305035 PMID: 17913967
43. Liao CH, Hsiao YM, Sheu GT, Chang JT, Wang PH, et al. (2007) Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae. Biochem Pharmacol 74:1541-1554. doi: 10.1016/j.bcp. 2007.07.025 PMID: 17720143
44. Hsu HY, Hua KF, Wu WC, Hsu J, Weng ST, et al. (2008) Reishi immuno-modulation protein induces interleukin-2 expression via protein kinase-dependent signaling pathways within human T cells. J Cell Physiol 215:15-26. doi: 10.1002/jcp. 21144 PMID: 18189229
45. Hu CT, Cheng CC, Pan SM, Wu JR, Wu WS (2013) PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2. Cell Signal 25:1457-1467. doi: 10.1016/j.cellsig.2013.03.011 PMID: 23524339
46. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, et al. (2013) First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 19:920-928. doi: 10.1158/1078-0432. CCR-12-2616 PMID: 23362325
47. Min L, He B, Hui L (2011) Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 21:10-20. doi: 10.1016/j.semcancer.2010.10.011 PMID: 20969960
48. Kudo M (2012) Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 18:6005-6017. doi: 10.3748/wjg.v18.i42.6005 PMID: 23155330
49. Zhang YH, Wang SQ, Sun CR, Wang M, Wang B, et al. (2011) Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro. Med Oncol 28:966-972. doi: 10.1007/s12032-010-9568-2 PMID: 20490718
50. Radtke S, Milanovic M, Rosse C, De Rycker M, Lachmann S, et al. (2013) ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci 126:2381-2391. doi: 10.1242/jcs.115832 PMID: 23549785
51. Chiang KC, Tsui KH, Chung LC, Yeh CN, Chen WT, et al. (2014) Celastrol blocks interleukin-6 gene expression via downregulation of NF-kappaB in prostate carcinoma cells. PLoS One 9:e93151. doi: 10.1371/journal.pone.0093151 PMID: 24664372
52. Li T, Xu WS, Wu GS, Chen XP, Wang YT, et al. (2014) Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells. Asian Pac J Cancer Prev 15:1745-1749. PMID: 24641402
53. Fu WM, Zhang JF, Wang H, Xi ZC, Wang WM, et al. (2012) Heat shock protein 27 mediates the effect of 1, 3, 5-trihydroxy-13, 13-dimethyl-2H-pyran [7, 6-b] xanthone on mitochondrial apoptosis in hepatocellular carcinoma. J Proteomics 75:4833-4843. doi: 10.1016/j.jprot.2012.05.032 PMID: 22677112
54. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and invasion by downregulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275:44-53. doi: 10.1016/j.canlet.2008.09.035 PMID: 19006648
55. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, et al. (2009) MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. Febs J 276:2966-2982. doi: 10.1111/j.1742-4658.2009.07014.x PMID: 19490101
56. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, et al. (2005) Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 4:1577-1584. doi: 10.1158/1535-7163. MCT-05-0106 PMID: 16227408
57. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300. doi: 10.1200/JCO. 2005.01.3441 PMID: 16908937
58. Villanueva A, Llovet JM (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140:1410-1426. doi: 10.1053/j.gastro.2011.03.006 PMID: 21406195
59. Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, et al. (2012) Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer 106:1997-2003. doi: 10.1038/bjc.2012.145 PMID: 22596232